Stock 6160 BEIGENE, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News BeiGene, Ltd. Hong Kong S.E.

Equities

6160

KYG1146Y1017

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:27 2024-07-12 am EDT 		5-day change 1st Jan Change
93.2 HKD +4.48% Intraday chart for BeiGene, Ltd. +5.19% -15.35%
Jul. 12 Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading MT
Jul. 01 Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading
MT
Zymeworks to Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
AQ
Neuroendocrine Tumors Pipeline 2024 | Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene
AQ
Advanced Hepatocellular Carcinoma Pipeline 2024 | CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene
AQ
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note
MT
Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing
MT
Beigene Insider Sold Shares Worth $368,162, According to a Recent SEC Filing
MT
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
AQ
BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Health Care Sector Index
CI
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma
MT
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
BU
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
CI
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
BU
Beijing Gene Announces Dose the First Five Patients in Its First-In-Human Phase 1 Trial to Evaluate BG-68501
CI
Beigene Issues Shares Under Incentive Schemes
MT
Transcript : BeiGene, Ltd. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01:20 PM
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy
MT
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
BU
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study
MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. 6160 Stock
  5. News BeiGene, Ltd.